Exploring the link between diabetes and pancreatic cancer

Margherita Pizzato, Federica Turati, Valentina Rosato & Carlo La Vecchia

To cite this article: Margherita Pizzato, Federica Turati, Valentina Rosato & Carlo La Vecchia (2019): Exploring the link between diabetes and pancreatic cancer, Expert Review of Anticancer Therapy, DOI: 10.1080/14737140.2019.1642109

To link to this article: https://doi.org/10.1080/14737140.2019.1642109
Special report

Exploring the link between diabetes and pancreatic cancer
Margherita Pizzato¹, Federica Turati¹, Valentina Rosato² and Carlo La Vecchia³*

¹Department of Clinical Sciences and Community Health, Università degli Studi di Milano, via Vanzetti 5, 20133 Milan, Italy
²Unit of Medical Statistics and Biometry, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via G. Venezian 1, 20133, Milano, Italy

*Correspondence to: Carlo La Vecchia, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, via Vanzetti 5, 20133 Milan, Italy, Email: carlo.lavecchia@unimi.it
Abstract

Introduction: Epidemiological studies indicate an association between type 2 diabetes and pancreatic cancer but the complex and multidirectional relationship between them remains unclear.

Areas covered: We summarized epidemiological evidence on diabetes and pancreatic cancer exploring the time-risk relationship. We described mechanisms linking long-standing diabetes to pancreatic cancer. We discussed pancreatic cancer-associated diabetes and its implication in the early detection of pancreatic cancer.

Expert opinion: The markedly increased risk of pancreatic cancer in patients with new-onset diabetes compared with long-standing diabetes indicates a complex and bidirectional connection, with long-standing diabetes being a predisposing factor for pancreatic cancer (increasing the risk of the malignancy 1.5- to 2-fold) and new-onset diabetes an early manifestation of the tumour. Identifying clinical features and biomarkers to distinguish pancreatic cancer-associated diabetes from type 2 diabetes is an important goal to improve management and survival of this cancer. Imaging (MRI) for middle age patients with new-onset diabetes may be considered.

Keywords: pancreatic cancer; review; type 2 diabetes; type 3c diabetes

Article highlights

- Pancreatic cancer is frequently recognized at an advanced stage and has a dismal prognosis.
- Epidemiological studies indicate a complex and multidirectional relationship between type 2 diabetes and pancreatic cancer.
- The risk of pancreatic cancer is greatest early after the diagnosis of diabetes and then it decreases, while remaining elevated many years after the diagnosis.
- Time-related aspects of the association between diabetes and pancreatic cancer suggest that long-standing diabetes is a risk factor for pancreatic cancer, increasing the risk 1.5- to 2-fold, while new-onset diabetes is an early manifestation of the tumour.
- Possible mechanisms for a direct link between long-standing diabetes and pancreatic cancer include resistance and compensatory hyperinsulinemia, elevated levels of circulating insulin-like growth factors, hyperglycemia and low chronic inflammation.
- The association between long-standing diabetes and pancreatic cancer may be in part due to shared risk factors between such two conditions, namely overweight/obesity, as well as to the increased medical surveillance of patients with a diagnosis of diabetes or pancreatic cancer.
- Pancreatic cancer-associated diabetes is likely a paraneoplastic effect.
- Diabetes caused by pancreatic cancer may be a clinical marker of underlying asymptomatic cancer. Identify clinical features and biomarkers to distinguish cancer-associated from type 2 diabetes may allow for earlier detection of pancreatic cancer, and hence improve management and survival.
1. Introduction

Over 90% of pancreatic cancers are adenocarcinomas of the exocrine pancreas. The adenocarcinoma of the exocrine pancreas is an aggressive tumor frequently recognized at advanced stage [1]. Therapies often have an unsatisfactory impact and the 5-year relative survival rate is <10% (~3% for metastatic cancer) [2]. In contrast to most other cancers, mortality due to pancreatic cancer has not declined over the most recent years [3-6].

Tobacco smoking is an established cause for pancreatic cancer [7], being responsible for 15-25% of cancers in various populations [7-10]. Other risk factors include history of (chronic) pancreatitis, obesity, diabetes and metabolic syndrome, heavy alcohol consumption and, possibly, selected aspects of diet [11-13], although the issue of diet and pancreatic cancer remains largely unclear.

The association between diabetes mellitus and pancreatic cancer has been noted since the mid 1800s [14], yet the complex and multidirectional relationship remains unclear. A higher than 2-fold increase in risk of pancreatic cancer was reported by earlier studies for diabetic patients compared to individuals without diabetes [15-18]. A real association is likely to exist [19], although this is probably more modest than previously supposed [20]. Studies assessing time-related aspects consistently indicate a negative relationship between diabetes duration and the risk of pancreatic cancer, with a peak rise in risk early after the diagnosis of diabetes that progressively decreases, while remaining elevated for many years. Such observations suggest bidirectional causality, indicating that diabetes is associated with an increased risk of pancreatic cancer and which may be the result of (subclinical) malignancy [21].

We herein summarize meta-analyses on the association between diabetes (mainly diabetes type II) and pancreatic cancer and discussed the largest original epidemiological studies that have been published over recent years, with the aim of providing a quantification of the association, and of the related time-risk relationship. We also discussed mechanisms linking long-standing diabetes to pancreatic cancer, pancreatic cancer-associated diabetes and its potential implications in the early detection of this cancer.

2. Epidemiological studies on diabetes and pancreatic cancer

Since the 1980s, several studies investigated the association between type 2 diabetes and the risk of pancreatic cancer. Findings of these studies have been reviewed and summarized in various reports [11,19,20,22-29], including at least 5 meta-analyses [20,22-24,27] (Table 1).

A meta-analysis, published in 1995, found a doubled risk for subjects with diabetes based on 20 studies [22]. In 2005, a meta-analysis of 36 studies estimated a summary relative risk (RR) of pancreatic cancer of 1.82 (95% confidence interval, CI, 1.66–1.89) for diabetic patients compared to non-diabetics [20]. Patients diagnosed with diabetes within 4 years prior to cancer diagnosis had a 50% greater risk of pancreatic cancer compared to patients with a longer history of the disease. The RR of patients with diabetes for 10 years or over was around 1.5. A subsequent meta-analysis of 35 cohort studies showed a summary RR for diabetes of 1.94 (95% CI, 1.66–2.27) with the results being consistent after body mass index (BMI) and smoking adjustment. This meta-analysis also found an inverse relationship between the duration of diabetes and the risk of pancreatic cancer [23]. Based on 50 cohort and 39 case-control studies published up to 2013, Batabyal. et al [24] estimated a summary RR of pancreatic cancer for diabetic subjects of 1.97 (95% CI, 1.78-2.18). This was similar in studies adjusting for smoking or not. As in the previous reports, the risk of pancreatic cancer was markedly increased after diabetes diagnosis; it then decreased, but remained elevated by 36% long after the diagnosis. Another meta-analysis, published in 2015, found a 60% increased pancreatic cancer risk for duration of diabetes ≥2 years versus no diabetes. For diabetes duration ≥10 years, there was a 50% increase in risk [27]. Publication bias did not affect those results [23,27].

In 2015, an umbrella review on type 2 diabetes and cancer [30] reported that the association with diabetes was not convincing for pancreatic cancer, as well as for a number of other cancer types. A likely explanation was the use of very stringent criteria to define a valid and “robust” association [31]. Specifically, pancreatic cancer was not included among cancers with convincing association with diabetes mainly because the 95% prediction interval included unity [23].

Since the publication of the last meta-analysis, several epidemiological investigations have become available. Among them, a pooled analysis of 15 case–control studies (Pancreatic Cancer Case-Control Consortium, Panc4), 9 of which already considered in the previous meta-analysis by Batabyal et al [24], included about 8300 cases and almost 14,000 controls and estimated an overall odds ratio (OR) of 1.90.
Information Classification: General
3. Expert opinion

Epidemiological evidence indicates a direct association between type 2 diabetes and pancreatic cancer and supports an inverse relation with diabetes duration. In particular, the observed risk of pancreatic cancer is greatest early after the diagnosis of diabetes and it progressively decreases, while remaining elevated many years after diabetes detection. The markedly higher risk of pancreatic cancer in patients with new-onset diabetes compared with long-standing diabetes suggests a complex and bidirectional connection: on one side, long-standing diabetes is a predisposing factor for pancreatic cancer development, increasing the risk of the malignancy around 1.5- to 2-fold; on the other side, new-onset diabetes may be a consequence or an early manifestation of pancreatic cancer [51]. In the latter context, diabetes secondary to pancreatic cancer usually develops within 24-36 months prior to the diagnosis of the cancer [52].

3.1 Long-standing diabetes

Several mechanisms have been suggested to clarify the association between long-standing diabetes and pancreatic cancer.

A hypothesis includes insulin resistance and compensatory high levels of insulin secretion (overproduced in type 2 diabetes mellitus until β-cell failure) [51,53]. In a pooled-analysis of 5 US prospective cohorts, the RRs for the upper versus lower quintile were 1.57 (95% CI, 1.08-2.30) for prediagnostic serum insulin and 2.22 (95% CI, 1.50-3.29) for prediagnostic proinsulin. Such associations became progressively stronger considering only cases developed after 5 or 10 years of follow-up, indicating that elevated biomarkers were not likely due to preclinical cancer [54]. Similarly, a prospective study estimated a two-fold pancreatic cancer risk (95% CI, 1.0-3.9) among individuals in the upper versus the lower quartile of insulin level, after excluding patients diagnosed within the first 5 years of follow-up, and also reported direct associations with baseline insulin resistance and higher glucose concentration [55]. Again, the associations were stronger after a longer time of follow-up. A role of hyperinsulinemia in the risk of pancreatic cancer is also supported by the observation that obese patients undergoing bariatric surgery (who typically show hyperinsulinemia) had a 50% reduction in the risk of pancreatic cancer compared to obese nonsurgical patients [56].

Both a direct effect of insulin and an indirect action involving growth hormone (GH)/insulin-like growth factor (IGF) axis could explain the increase in risk of hyperinsulinemic patients. Pancreatic β-cells release insulin in the intrapancreatic portal vessels [51] that lap acinar and ductal cells [57]. Thus, insulin exerts a proxicrine effect on receptors of exocrine pancreatic cells that, once activated, convey survival and proliferation signals [19] involved in carcinogenesis [58]. Insulin may also indirectly promote cancerogenesis acting on GH/IGF axis [19]. IGF receptors, expressed in pancreatic cancer cells, codify antiapoptotic and angiogenic signals which promote tumor development. Insulin increases levels of free and bioactive IGF-1, reducing hepatic production of IGF binding protein (IGFBP). Further, IGF-1 and insulin receptors are structurally similar, thus insulin and IGF-1 could activate both receptors. High IGF1 and hyperinsulinemia, that occurs in insulin resistant individuals, act synergically in promoting cancerogenesis [28]. In line with the hyperinsulinemic hypothesis [53], treatments improving insulin resistance, namely metformin, might reduce pancreatic cancer risk, whereas therapies that stimulate endogenous release of insulin, such as sulfonylureas, may increase the risk [59], although evidence is unclear [60].

In addition, a possible role of hyperglycemia in the diabetes-pancreatic cancer association has been suggested [28,53]. Hyperglycemia can attenuate antioxidant enzyme activity and enhance free radical formation, leading to a state of oxidative stress. Hyperglycemia is associated with increased levels of advanced glycation end products (AGE), whose receptor binds several ligands implicated in inflammation and cancer process [51]. Moreover, hyperglycaemic conditions may facilitate neoplastic proliferation [61]. Nonetheless, glucose uptake mechanisms may not add a further growth advantage [19].

Overweight, that frequently characterized type 2 diabetes, could play a crucial role in carcinogenesis [62,63]. Adipose tissue is a complex endocrine organ able to secrete a variety of bioactive molecules (cytokines, free fatty acids, TNFα, plasminogen activator inhibitor-1 (PAI-1) and adiponectin) which may lead malignant transformation and progression [64]. Further, adipose tissue microenvironment promotes concomitant systemic endocrine alterations (obesity-related insulin resistance, hyperinsulinemia, sustained hyperglycemia) which, in turn, are involved in cancer development [65]. However, an increased risk of pancreatic cancer among diabetic subjects was evident also after adjusting for anthropometric factors (mainly BMI) [7,23,36,38] and in subgroup defined by BMI [7,36], thus indicating that obesity is unlikely to
explain the observed association, although some degree of under-adjustment is possible. Further, RRs for the diabetes-pancreatic cancer association are similar in studies adjusting and not adjusting for smoking [23,24]. In addition, the direct association between prediabetes and pancreatic cancer risk [66] supports the relationship between diabetes and pancreatic cancer.

Diagnostic bias may contribute in part to the observed increased risk. Indeed, an increased medical surveillance has been documented for patients with type 2 diabetes [67]. The risk of the malignancy declines with the increasing duration of diabetes. Such downward trend in risk might be explained through a decreased role of diagnostic bias, besides a possible additional role of a decreased secretion of endogenous insulin, lifestyle changes after diabetes diagnosis and the use of metformin and selected glucose-lowering medications.

3.2 New onset diabetes
The risk of pancreatic cancer is highly increased until a couple of years from diabetes diagnosis, suggesting that the cancer itself lead to the onset of diabetes.

Pancreatic cancer-induced diabetes has been classified as pancreatogenic type 3c diabetes mellitus [68]. However, only a small proportion (<10%) of type 3c diabetes (which accounts for <10% of total diabetes) is attributed to pancreatic neoplasia, while the majority (75-80%) is associated to chronic pancreatitis [51]. Concurrent diabetes and chronic pancreatitis increased the risk of pancreatic cancer by 5- to over 30-fold [69-71].

The hypothesis that pancreatic cancer induces diabetes is supported by the observations that roughly half of the newly diagnosed pancreatic cancer patients have diabetes at the time of diagnosis, which is frequently (>50%) new-onset having developed over the 2-3 years preceding the diagnosis of pancreatic cancer [52,72]. Not all new onset diabetes is type 3c diabetes mellitus (assuming that type 3c diabetes mellitus is a well-defined, independent syndrome), but, in a proportion of patients with new-onset diabetes, resection of the tumor is followed by diabetes resolution [72]. In an Italian multicentric case-control study, diabetes was diagnosed concomitantly with pancreatic cancer in 40% of patients and within 2 years before the diagnosis of cancer in 16% [73].

The physiopathology linking type 3c diabetes mellitus to pancreatic cancer is still poorly understood. Diabetes secondary to pancreatic cancer may be the result of a glandular destruction due to tumour infiltration and ductal obstruction. However, diabetes in pancreatic cancer patients is mainly characterized by hyperinsulinaemia secondary to insulin resistance. Therefore, diabetes secondary to pancreatic cancer is likely a paraneoplastic effect: mediators released by the cancer interfere with insulin secretion or insulin action [74]. This is supported by the evidence that treatments (resection or chemotherapy) of pancreatic cancer often lead to improvement in hyperglycemia [72]. In addition, a direct role of pancreatic cancer in new onset diabetes is supported by the finding that glucose tolerance improves after tumour treatment in patients with new-onset diabetes secondary to pancreatic cancer, whilst it does not improve in long-standing diabetes [75].

In any case, the peak of pancreatic cancer risk within the first years since diabetes detection may be inflated by the heightened surveillance following diabetes diagnosis.

3.3 New onset diabetes for the early detection of pancreatic cancer
The 5-year relative survival rate of pancreatic cancer is around 5%, and ranges between around 35% for localized cancers (which represent a small fraction of cancers) and 3% for metastatic ones [2]. The detection of pancreatic cancer is often delayed because symptoms are often aspecific (e.g., weight loss, jaundice, nausea) and occur in an advanced stage. Thus, early detection of pancreatic cancer when it is still asymptomatic, and therapeutic options are available, is an important goal for improving pancreatic cancer management and survival.

New-onset diabetes caused by the cancer is a possible clinical marker of underlying asymptomatic pancreatic cancer. Therefore, the identification of patients with cancer-associated diabetes could offer the opportunity for the early detection of the malignancy [68]. According to a population-based cohort study, the 3-year cumulative incidence of pancreatic cancer among newly diagnosed diabetic patients aged ≥50 years was 0.85%, over 6-fold higher than the general population [76]. Although mass screening for
pancreatic cancer in all patients with new-onset diabetes is still open to discussion [77], imaging (MRI) of the pancreas may be considered for middle age and elderly subjects (≥50 years) developing diabetes. Some further indications to distinguish pancreatic cancer-associated diabetes from other types of diabetes may derive from clinical features atypical for type 2 diabetes, such as rapidly altered glycemic indices, weight loss in the preceding months prior to diabetes onset, absence of typical characteristics of the metabolic syndrome, and family history [74]. Notably, a case-control study indicated that elevated glucose levels precede the diagnosis of pancreatic cancer by 30-36 months [78].

Two studies developed and validated clinical prediction models to identify high-risk individuals among those with newly diagnosed diabetes who might benefit from pancreatic cancer screening. One clinical model included age at diabetes diagnosis and change in weight and in blood glucose and stratified patients in 3 risk groups. The cut-off for the very high-risk group had sensitivity and specificity of 80% [79]. A further model was based on age, BMI, change in BMI, smoking, use of antidiabetic medications, serum levels of HbA1C, and other selected markers, and had 45% sensitivity and 94% specificity, and a positive predictive value of 2.6% [80]. However further validation is need.

It is likely that a combination of biomarkers and clinicopathologic characteristics of diabetic patients is useful in early cancer detection. Although no biomarker is currently validated to differentiate between type 2 diabetes and cancer-associated diabetes, evidence shows the potential relevance of some molecules [81]. In particular, the most convincing ones include Vanin-1 (VNN1) [82], Adrenomedullin [83], CA19-9 and CEA [84], glucagon/insulin ratio [85] and a deficient pancreatic polypeptide (PP) response to nutrient ingestion [86].

Future research may identify predictive models and/or sensitive and specific biomarkers for the identification of occult pancreatic cancer in patients with new-onset diabetes, and develop an efficient and cost-effective interventional screening protocol for newly diagnosed diabetic patients that includes imaging and/or clinical algorithms. In this context, valuable data may be generated in the next years by the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Initiated in 2015, the CPDPC aims to assemble a cohort of 10,000 subjects ≥50 years with new onset diabetes to address to the challenges posed by early detection of pancreatic cancer [87].

**Funding**
This work was partly supported by Department Funding and the Italian League against cancer.

**Declaration of interest**
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

**Reviewer disclosures**
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

**Acknowledgments**
The authors thank their colleague Linia Patel for English revision of the manuscript.
References


- A meta-analysis of 88 observational studies published up to 2013 investigating the association between diabetes, diabetes duration and pancreatic cancer


28. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012;51:64-74


- A pooled-analysis of 15 case–control studies within the Pancreatic Cancer Case-Control Consortium (Panc4) which focused on the temporal relationship between diagnosis of diabetes and onset of pancreatic cancer


50. Ohkuma T, Peters SAE, Woodward M. Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia 2018;61:2140-54


- A review describing the current understanding of the interrelationships between diabetes, diabetes management, and pancreatic cancer, and areas where additional research is needed


- A review addressing methodological aspects underpinning the interpretations of links between diabetes and cancer incidence


- A review on the epidemiology, pathogenesis, and clinical relevance of type 3c diabetes secondary to chronic pancreatitis and pancreatic ductal adenocarcinoma


- A population-based cohort study estimating a 0.85% 3-year cumulative incidence of pancreatic cancer among new-onset diabetic patients aged ≥50 years


- A review exploring the opportunities and challenges for the early detection of pancreatic cancer, with a focus on elderly patients with new-onset diabetes.


<table>
<thead>
<tr>
<th>Reference</th>
<th>N. of included studies</th>
<th>Summary RR (95% CI) for diabetes</th>
<th>Heterogeneity (p; I²)</th>
<th>Summary RR (95% CI) for time since diabetes (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Song et al, 2015 [27]</td>
<td>26 cohort(^{§})</td>
<td>≥2 years since diabetes:</td>
<td></td>
<td>≥5 (26 studies): 1.58 (1.41-1.75)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>overall: 1.64 (1.52-1.78)</td>
<td>overall: p&lt;0.001; 52.1%</td>
<td>≥10 (14 studies): 1.50 (1.28-1.75)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cohort: 1.56 (1.42-1.71)</td>
<td>cohort: p=0.001; 54.6%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>nested: 1.88 (1.53-2.30)</td>
<td>nested: p=0.679; 0%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>case-control: 1.75 (1.44-2.12)</td>
<td>case-control: p=0.004; 52.9%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>cohort: 1.88 (1.71-2.07)</td>
<td>cohort: &lt;0.001; 91%</td>
<td>1-4 (21 studies): 1.86 (1.56-2.21)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>case-control: 2.08 (1.87-2.32)</td>
<td>case-control: &lt;0.001; 65%</td>
<td>5-9 (23 studies): 1.72 (1.47-2.00)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥10 (28 studies): 1.36 (1.19-1.55)</td>
</tr>
<tr>
<td>Ben et al, 2011 [23]</td>
<td>35 cohort(^{§})</td>
<td>cohort: 1.94 (1.66–2.27)</td>
<td>cohort: p&lt;0.001; 93.6%</td>
<td></td>
</tr>
<tr>
<td>Huxley et al, 2005 [20]</td>
<td>19 cohort(^{§})</td>
<td>overall: 1.82 (1.66-1.89)</td>
<td>overall: NA</td>
<td>&lt;4 (9 studies): 2.05 (1.87-2.25)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cohort: 1.73 (1.59-1.88)</td>
<td>cohort: p=0.05</td>
<td>5-9 (9 studies): 1.54 (1.31-1.81)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>case-control: 1.94 (1.53-2.46)</td>
<td>case-control: p=0.002</td>
<td>≥10 (7 studies): 1.51 (1.16-1.96)</td>
</tr>
<tr>
<td>Everhart &amp; Wright, 1995 [22]</td>
<td>9 cohort(^{§})</td>
<td>≥1 year since diabetes:</td>
<td></td>
<td>≥5 (11 studies): 2.0 (1.2-3.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>overall: 2.1 (1.6-2.8)</td>
<td>overall: p=0.003</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>cohort: 2.6 (1.6-4.1)</td>
<td>cohort: NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>case-control: 1.8 (1.1-2.7)</td>
<td>case-control: NA</td>
<td></td>
</tr>
</tbody>
</table>

\(^{§}\) Including nested case-control studies. NA: not available.